Castration-Resistant Prostate Cancer (CRPC) Treatment Market Snapshot (2023 to 2033)

The global castration-resistant prostate cancer (CRPC) treatment market is expected to garner a market value of US$ 11.3 Billion in 2023 and is expected to accumulate a market value of US$ 28 Billion by registering a CAGR of 9.5% in the forecast period 2023 to 2033. Growth of the castration-resistant prostate cancer (CRPC) treatment market can be attributed to increasing prevalence of the ailment and use of combination therapies to treat the ailment. The market for castration-resistant prostate cancer (CRPC) treatment registered a CAGR of 6% in the historical period 2018 to 2022

Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer that has become resistant to traditional hormone therapy (also known as androgen deprivation therapy or ADT). In CRPC, the cancer continues to grow despite low levels of testosterone in the body, which is typically the result of surgical or medical castration.

Report Attribute Details
Expected Market Value (2023) US$ 11.3 Billion
Anticipated Forecast Value (2033) US$ 28 Billion
Projected Growth Rate (2023 to 2033) 9.5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Castration-Resistant Prostate Cancer (CRPC) Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Castration-Resistant Prostate Cancer (CRPC) Treatment reflected a value of 6% during the historical period, 2018 to 2022.

Increasing prevalence of prostate cancer, the development of new therapies, and the rising demand for personalized medicine is driving the growth of the castration-resistant prostate cancer (CRPC) treatment market. Moreover, research and development along with technological integration for innovating medication is expected to bolster the demand for treatment of castration-resistant prostate cancer (CRPC) treatment market.

Thus, the market for Castration-Resistant Prostate Cancer (CRPC) Treatment is expected to register a CAGR of 9.5% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

Availability of diagnostic tools shaping landscape for CRPC market

The increasing incidence of prostate cancer, which is one of the most common cancers among men, is driving the demand for effective treatments for CRPC. The development of new treatment options, including targeted therapies, immunotherapies, and radiopharmaceuticals, has expanded the range of options available for the treatment of CRPC.

The aging population is more susceptible to prostate cancer and CRPC, and this demographic trend is increasing the demand for effective treatments for this disease. The availability of diagnostic tools such as imaging technologies, genomic testing, and liquid biopsies has improved the detection and monitoring of CRPC, which is contributing to the demand for effective treatments.

The increasing research and development activities in the field of oncology, including prostate cancer, are leading to the development of new and innovative treatments for CRPC. The government initiatives aimed at increasing awareness of prostate cancer and improving access to healthcare services are contributing to the growth of the CRPC treatment market.

Presence of different treatments creative lucrative opportunities for CRPC market

Second-line hormone therapy: This involves the use of different types of hormone therapy drugs that target different aspects of the androgen receptor pathway.

Chemotherapy: Chemotherapy drugs such as docetaxel and cabazitaxel may be used to treat CRPC.

Immunotherapy: Immune checkpoint inhibitors such as pembrolizumab and nivolumab have been approved for the treatment of certain types of CRPC.

Radiopharmaceutical therapy: Radiopharmaceuticals such as radium-223 and lutetium-177 PSMA have been approved for the treatment of CRPC that has spread to the bones.

Targeted therapy: Targeted drugs such as enzalutamide, abiraterone, and apalutamide may be used to treat CRPC by blocking specific pathways that fuel the growth of cancer cells.

Clinical trials: Participation in clinical trials of new treatments is also an option for some patients with CRPC.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

Limited efficiency of treatments along with expensive nature of treatment affecting market growth

Many of the available treatment options for CRPC are expensive, and this can make them inaccessible to patients who cannot afford them or are not covered by health insurance. The side effects of many CRPC treatments, such as chemotherapy and immunotherapy, can be severe and impact a patient's quality of life. This can make it challenging for patients to tolerate the treatments and continue with their treatment plans.

While there are several treatment options available for CRPC, not all of them are effective for every patient. Some patients may not respond to certain treatments, and this can limit the efficacy of the available options. Some patients may develop resistance to the available treatments, which can make it challenging to manage their disease and prolong their survival.

Despite the advances in research and development, the underlying mechanisms of CRPC are not fully understood, and this can make it challenging to develop new and more effective treatments. Developing new treatments for CRPC can be challenging due to regulatory requirements, including the need for extensive clinical trials to demonstrate safety and efficacy. All these factors are derailing the growth of CRPC market.

Region-Wise Insights

Advanced Healthcare Infrastructure Boosting Market Growth of CRPC in North America?

Newer targeted therapies creating lucrative opportunities for CPRC treatment

The North American market for Castration-Resistant Prostate Cancer (CRPC) treatment is one of the largest markets in the world, due to the high prevalence of prostate cancer in the region and the availability of advanced healthcare infrastructure.

In terms of treatment options, chemotherapy and hormone therapy have been the mainstays of CRPC treatment in North America for many years, but newer targeted therapies such as abiraterone, enzalutamide, apalutamide, and radium-223 have also been approved for use. Immunotherapy, such as the use of immune checkpoint inhibitors, is also being investigated for CRPC treatment. Thus, North America is expected to possess 46% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.

Introduction of Novel Treatments Supporting Growth of CRPC Treatment Market in Europe?

Increasing awareness of diagnosis propelling demand for CRPC treatment in Europe

The Europe CRPC treatment market is being driven by the increasing prevalence of the disease in the region, as well as the growing awareness and diagnosis of the disease. In addition, the market is being driven by the introduction of novel treatments that offer better efficacy and fewer side effects than traditional therapies.

One of the most promising developments in CRPC treatment is the use of targeted therapies. These drugs are designed to specifically target the cancer cells and limit their growth and spread, while minimizing damage to healthy cells. Targeted therapies such as enzalutamide and abiraterone have shown significant benefits in treating CRPC, leading to their approval by regulatory agencies in Europe. Thus, Europe is expected to possess 40% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Ease and Accessibility of Consuming Oral Medications Making Them Popular for CRPC Treatment?

Ease to administer oral medication increasing dependency to treat CRPC treatment

The oral route offers patients the convenience of taking medication in the comfort of their own homes. This is particularly beneficial for CRPC patients, who may need to take medication for extended periods of time. Oral medications can be taken without the need for hospital visits or invasive procedures, making treatment more accessible and less disruptive to a patient's daily life.

In addition, the oral route of administration can help to improve patient adherence to treatment. Patients are more likely to take their medication as prescribed when it is delivered in a convenient, easy-to-administer format. This is particularly important in the treatment of CRPC, where adherence to therapy is crucial for achieving positive treatment outcomes. Thus, by drug delivery method, oral route is expected to possess 55% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.

Market Competition

Key players in the castration-resistant prostate cancer (CRPC) treatment market are Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc, Dendreon Corporation

  • In 2018, Sanofi and Regeneron Pharmaceuticals announced the results of a phase 3 clinical trial investigating the use of their immunotherapy drug, cemiplimab, in combination with Jevtana for the treatment of metastatic CRPC. The trial showed promising results, with the combination therapy significantly improving overall survival and progression-free survival compared to Jevtana alone.
  • In 2019, Pfizer announced the results of a phase 3 clinical trial investigating the use of Xtandi in combination with abiraterone acetate, another androgen receptor inhibitor, for the treatment of metastatic CRPC.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 11.3 Billion
Market Value in 2033 US$ 28 Billion
Growth Rate CAGR of 9.5% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Therapy Type
  • Drug Class
  • Drug Delivery Method
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Rest of Latin America
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Rest of South Asia
  • China
  • Japan
  • South Korea
  • Austria
  • New Zealand
  • GCC countries
  • South Africa
  • Israel
  • Rest of MEA
Key Companies Profiled
  • Sanofi S.A.
  • Johnson and Johnson
  • Pfizer, Inc.
  • Bayer AG
  • Abbott Laboratories
  • GlaxoSmithKline PLC
  • Northwest Biotherapeutics, Inc.
  • Active Biotech AB
  • Astellas Pharma, Inc
  • Dendreon Corporation
Customization Available Upon Request

Key Segments Profiled in the Castration-Resistant Prostate Cancer (CRPC) Treatment Industry Survey

Therapy Type:

  • Hormonal therapy
  • Chemotherapy
  • Immunotherapy
  • Radiotherapy

Drug Class:

  • Antineoplastic
  • Non-steroidal Antiandrogen
  • Corticosteroids
  • Microtubule Inhibitor

Drug Delivery Method:

  • Oral Route
  • Injectable Route

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA

Frequently Asked Questions

Which region holds high lucrativeness in the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

The Asia Pacific region is projected to emerge as a lucrative market for Castration-Resistant Prostate Cancer (CRPC) Treatment.

What is the growth potential of the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

The growth potential of the Castration-Resistant Prostate Cancer (CRPC) Treatment market is 8% through 2033.

What limits the growth potential of the Market?

The high cost of treatment is likely to limit market growth.

What is North America's expected share in 2023?

North America is likely to generate 46% revenue in 2023.

What is the Projected Size of the Market by 2033?

The global market size to reach US$ 28 billion by 2033.

Table of Content
1. Executive Summary | Castration-Resistant Prostate Cancer (CRPC) Treatment Market
    1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Market Background
    3.1. Market Dynamics
        3.1.1. Drivers
        3.1.2. Restraints
        3.1.3. Opportunity
        3.1.4. Trends
    3.2. Scenario Forecast
        3.2.1. Demand in Optimistic Scenario
        3.2.2. Demand in Likely Scenario
        3.2.3. Demand in Conservative Scenario
    3.3. Opportunity Map Analysis
    3.4. Investment Feasibility Matrix
    3.5. PESTLE and Porter’s Analysis
    3.6. Regulatory Landscape
        3.6.1. By Key Regions
        3.6.2. By Key Countries
    3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
        4.2.1. Y-o-Y Growth Trend Analysis
        4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type
    5.1. Introduction / Key Findings
    5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022
    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033
        5.3.1. Hormonal therapy
        5.3.2. Chemotherapy
        5.3.3. Immunotherapy
        5.3.4. Radiotherapy
    5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022
    5.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
    6.1. Introduction / Key Findings
    6.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
        6.3.1. Antineoplastic
        6.3.2. Non-steroidal Antiandrogen
        6.3.3. Corticosteroids
        6.3.4. Microtubule Inhibitor
    6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
    6.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Delivery Method 
    7.1. Introduction / Key Findings
    7.2. Historical Market Size Value (US$ Million) Analysis By Drug Delivery Method , 2018 to 2022
    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Delivery Method , 2023 to 2033
        7.3.1. Oral Route
        7.3.2. Injectable Route
    7.4. Y-o-Y Growth Trend Analysis By Drug Delivery Method , 2018 to 2022
    7.5. Absolute $ Opportunity Analysis By Drug Delivery Method , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
    8.1. Introduction / Key Findings
    8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
    9.1. Introduction
    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
        9.3.1. North America
        9.3.2. Latin America
        9.3.3. Europe
        9.3.4. South Asia
        9.3.5. East Asia
        9.3.6. Oceania
        9.3.7. MEA
    9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        10.2.1. By Country
            10.2.1.1. USA
            10.2.1.2. Canada
        10.2.2. By Therapy Type
        10.2.3. By Drug Class
        10.2.4. By Drug Delivery Method
        10.2.5. By Distribution Channel
    10.3. Market Attractiveness Analysis
        10.3.1. By Country
        10.3.2. By Therapy Type
        10.3.3. By Drug Class
        10.3.4. By Drug Delivery Method
        10.3.5. By Distribution Channel
    10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        11.2.1. By Country
            11.2.1.1. Brazil
            11.2.1.2. Mexico
            11.2.1.3. Rest of Latin America
        11.2.2. By Therapy Type
        11.2.3. By Drug Class
        11.2.4. By Drug Delivery Method
        11.2.5. By Distribution Channel
    11.3. Market Attractiveness Analysis
        11.3.1. By Country
        11.3.2. By Therapy Type
        11.3.3. By Drug Class
        11.3.4. By Drug Delivery Method 
        11.3.5. By Distribution Channel
    11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        12.2.1. By Country
            12.2.1.1. Germany
            12.2.1.2. United Kingdom
            12.2.1.3. France
            12.2.1.4. Spain
            12.2.1.5. Italy
            12.2.1.6. Rest of Europe
        12.2.2. By Therapy Type
        12.2.3. By Drug Class
        12.2.4. By Drug Delivery Method
        12.2.5. By Distribution Channel
    12.3. Market Attractiveness Analysis
        12.3.1. By Country
        12.3.2. By Therapy Type
        12.3.3. By Drug Class
        12.3.4. By Drug Delivery Method
        12.3.5. By Distribution Channel
    12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        13.2.1. By Country
            13.2.1.1. India
            13.2.1.2. Malaysia
            13.2.1.3. Singapore
            13.2.1.4. Thailand
            13.2.1.5. Rest of South Asia
        13.2.2. By Therapy Type
        13.2.3. By Drug Class
        13.2.4. By Drug Delivery Method
        13.2.5. By Distribution Channel
    13.3. Market Attractiveness Analysis
        13.3.1. By Country
        13.3.2. By Therapy Type
        13.3.3. By Drug Class
        13.3.4. By Drug Delivery Method
        13.3.5. By Distribution Channel
    13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        14.2.1. By Country
            14.2.1.1. China
            14.2.1.2. Japan
            14.2.1.3. South Korea
        14.2.2. By Therapy Type
        14.2.3. By Drug Class
        14.2.4. By Drug Delivery Method
        14.2.5. By Distribution Channel
    14.3. Market Attractiveness Analysis
        14.3.1. By Country
        14.3.2. By Therapy Type
        14.3.3. By Drug Class
        14.3.4. By Drug Delivery Method
        14.3.5. By Distribution Channel
    14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        15.2.1. By Country
            15.2.1.1. Australia
            15.2.1.2. New Zealand
        15.2.2. By Therapy Type
        15.2.3. By Drug Class
        15.2.4. By Drug Delivery Method
        15.2.5. By Distribution Channel
    15.3. Market Attractiveness Analysis
        15.3.1. By Country
        15.3.2. By Therapy Type
        15.3.3. By Drug Class
        15.3.4. By Drug Delivery Method
        15.3.5. By Distribution Channel
    15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        16.2.1. By Country
            16.2.1.1. GCC Countries
            16.2.1.2. South Africa
            16.2.1.3. Israel
            16.2.1.4. Rest of MEA
        16.2.2. By Therapy Type
        16.2.3. By Drug Class
        16.2.4. By Drug Delivery Method
        16.2.5. By Distribution Channel
    16.3. Market Attractiveness Analysis
        16.3.1. By Country
        16.3.2. By Therapy Type
        16.3.3. By Drug Class
        16.3.4. By Drug Delivery Method
        16.3.5. By Distribution Channel
    16.4. Key Takeaways
17. Key Countries Market Analysis
    17.1. USA
        17.1.1. Pricing Analysis
        17.1.2. Market Share Analysis, 2022
            17.1.2.1. By Therapy Type
            17.1.2.2. By Drug Class
            17.1.2.3. By Drug Delivery Method
            17.1.2.4. By Distribution Channel
    17.2. Canada
        17.2.1. Pricing Analysis
        17.2.2. Market Share Analysis, 2022
            17.2.2.1. By Therapy Type
            17.2.2.2. By Drug Class
            17.2.2.3. By Drug Delivery Method
            17.2.2.4. By Distribution Channel
    17.3. Brazil
        17.3.1. Pricing Analysis
        17.3.2. Market Share Analysis, 2022
            17.3.2.1. By Therapy Type
            17.3.2.2. By Drug Class
            17.3.2.3. By Drug Delivery Method
            17.3.2.4. By Distribution Channel
    17.4. Mexico
        17.4.1. Pricing Analysis
        17.4.2. Market Share Analysis, 2022
            17.4.2.1. By Therapy Type
            17.4.2.2. By Drug Class
            17.4.2.3. By Drug Delivery Method
            17.4.2.4. By Distribution Channel
    17.5. Germany
        17.5.1. Pricing Analysis
        17.5.2. Market Share Analysis, 2022
            17.5.2.1. By Therapy Type
            17.5.2.2. By Drug Class
            17.5.2.3. By Drug Delivery Method
            17.5.2.4. By Distribution Channel
    17.6. United Kingdom
        17.6.1. Pricing Analysis
        17.6.2. Market Share Analysis, 2022
            17.6.2.1. By Therapy Type
            17.6.2.2. By Drug Class
            17.6.2.3. By Drug Delivery Method
            17.6.2.4. By Distribution Channel
    17.7. France
        17.7.1. Pricing Analysis
        17.7.2. Market Share Analysis, 2022
            17.7.2.1. By Therapy Type
            17.7.2.2. By Drug Class
            17.7.2.3. By Drug Delivery Method
            17.7.2.4. By Distribution Channel
    17.8. Spain
        17.8.1. Pricing Analysis
        17.8.2. Market Share Analysis, 2022
            17.8.2.1. By Therapy Type
            17.8.2.2. By Drug Class
            17.8.2.3. By Drug Delivery Method
            17.8.2.4. By Distribution Channel
    17.9. Italy
        17.9.1. Pricing Analysis
        17.9.2. Market Share Analysis, 2022
            17.9.2.1. By Therapy Type
            17.9.2.2. By Drug Class
            17.9.2.3. By Drug Delivery Method
            17.9.2.4. By Distribution Channel
    17.10. India
        17.10.1. Pricing Analysis
        17.10.2. Market Share Analysis, 2022
            17.10.2.1. By Therapy Type
            17.10.2.2. By Drug Class
            17.10.2.3. By Drug Delivery Method
            17.10.2.4. By Distribution Channel
    17.11. Malaysia
        17.11.1. Pricing Analysis
        17.11.2. Market Share Analysis, 2022
            17.11.2.1. By Therapy Type
            17.11.2.2. By Drug Class
            17.11.2.3. By Drug Delivery Method
            17.11.2.4. By Distribution Channel
    17.12. Singapore
        17.12.1. Pricing Analysis
        17.12.2. Market Share Analysis, 2022
            17.12.2.1. By Therapy Type
            17.12.2.2. By Drug Class
            17.12.2.3. By Drug Delivery Method
            17.12.2.4. By Distribution Channel
    17.13. Thailand
        17.13.1. Pricing Analysis
        17.13.2. Market Share Analysis, 2022
            17.13.2.1. By Therapy Type
            17.13.2.2. By Drug Class
            17.13.2.3. By Drug Delivery Method
            17.13.2.4. By Distribution Channel
    17.14. China
        17.14.1. Pricing Analysis
        17.14.2. Market Share Analysis, 2022
            17.14.2.1. By Therapy Type
            17.14.2.2. By Drug Class
            17.14.2.3. By Drug Delivery Method
            17.14.2.4. By Distribution Channel
    17.15. Japan
        17.15.1. Pricing Analysis
        17.15.2. Market Share Analysis, 2022
            17.15.2.1. By Therapy Type
            17.15.2.2. By Drug Class
            17.15.2.3. By Drug Delivery Method
            17.15.2.4. By Distribution Channel
    17.16. South Korea
        17.16.1. Pricing Analysis
        17.16.2. Market Share Analysis, 2022
            17.16.2.1. By Therapy Type
            17.16.2.2. By Drug Class
            17.16.2.3. By Drug Delivery Method
            17.16.2.4. By Distribution Channel
    17.17. Australia
        17.17.1. Pricing Analysis
        17.17.2. Market Share Analysis, 2022
            17.17.2.1. By Therapy Type
            17.17.2.2. By Drug Class
            17.17.2.3. By Drug Delivery Method
            17.17.2.4. By Distribution Channel
    17.18. New Zealand
        17.18.1. Pricing Analysis
        17.18.2. Market Share Analysis, 2022
            17.18.2.1. By Therapy Type
            17.18.2.2. By Drug Class
            17.18.2.3. By Drug Delivery Method
            17.18.2.4. By Distribution Channel
    17.19. GCC Countries
        17.19.1. Pricing Analysis
        17.19.2. Market Share Analysis, 2022
            17.19.2.1. By Therapy Type
            17.19.2.2. By Drug Class
            17.19.2.3. By Drug Delivery Method
            17.19.2.4. By Distribution Channel
    17.20. South Africa
        17.20.1. Pricing Analysis
        17.20.2. Market Share Analysis, 2022
            17.20.2.1. By Therapy Type
            17.20.2.2. By Drug Class
            17.20.2.3. By Drug Delivery Method
            17.20.2.4. By Distribution Channel
    17.21. Israel
        17.21.1. Pricing Analysis
        17.21.2. Market Share Analysis, 2022
            17.21.2.1. By Therapy Type
            17.21.2.2. By Drug Class
            17.21.2.3. By Drug Delivery Method
            17.21.2.4. By Distribution Channel
18. Market Structure Analysis
    18.1. Competition Dashboard
    18.2. Competition Benchmarking
    18.3. Market Share Analysis of Top Players
        18.3.1. By Regional
        18.3.2. By Therapy Type
        18.3.3. By Drug Class
        18.3.4. By Drug Delivery Method
        18.3.5. By Distribution Channel
19. Competition Analysis
    19.1. Competition Deep Dive
        19.1.1. Sanofi S.A.
            19.1.1.1. Overview
            19.1.1.2. Product Portfolio
            19.1.1.3. Profitability by Market Segments
            19.1.1.4. Sales Footprint
            19.1.1.5. Strategy Overview
                19.1.1.5.1. Marketing Strategy
        19.1.2. Johnson and Johnson
            19.1.2.1. Overview
            19.1.2.2. Product Portfolio
            19.1.2.3. Profitability by Market Segments
            19.1.2.4. Sales Footprint
            19.1.2.5. Strategy Overview
                19.1.2.5.1. Marketing Strategy
        19.1.3. Pfizer, Inc.
            19.1.3.1. Overview
            19.1.3.2. Product Portfolio
            19.1.3.3. Profitability by Market Segments
            19.1.3.4. Sales Footprint
            19.1.3.5. Strategy Overview
                19.1.3.5.1. Marketing Strategy
        19.1.4. Bayer AG
            19.1.4.1. Overview
            19.1.4.2. Product Portfolio
            19.1.4.3. Profitability by Market Segments
            19.1.4.4. Sales Footprint
            19.1.4.5. Strategy Overview
                19.1.4.5.1. Marketing Strategy
        19.1.5. Abbott Laboratories
            19.1.5.1. Overview
            19.1.5.2. Product Portfolio
            19.1.5.3. Profitability by Market Segments
            19.1.5.4. Sales Footprint
            19.1.5.5. Strategy Overview
                19.1.5.5.1. Marketing Strategy
        19.1.6. GlaxoSmithKline PLC
            19.1.6.1. Overview
            19.1.6.2. Product Portfolio
            19.1.6.3. Profitability by Market Segments
            19.1.6.4. Sales Footprint
            19.1.6.5. Strategy Overview
                19.1.6.5.1. Marketing Strategy
        19.1.7. Northwest Biotherapeutics, Inc.
            19.1.7.1. Overview
            19.1.7.2. Product Portfolio
            19.1.7.3. Profitability by Market Segments
            19.1.7.4. Sales Footprint
            19.1.7.5. Strategy Overview
                19.1.7.5.1. Marketing Strategy
        19.1.8. Active Biotech AB
            19.1.8.1. Overview
            19.1.8.2. Product Portfolio
            19.1.8.3. Profitability by Market Segments
            19.1.8.4. Sales Footprint
            19.1.8.5. Strategy Overview
                19.1.8.5.1. Marketing Strategy
        19.1.9. Astellas Pharma, Inc.
            19.1.9.1. Overview
            19.1.9.2. Product Portfolio
            19.1.9.3. Profitability by Market Segments
            19.1.9.4. Sales Footprint
            19.1.9.5. Strategy Overview
                19.1.9.5.1. Marketing Strategy
        19.1.10. Dendreon Corporation
            19.1.10.1. Overview
            19.1.10.2. Product Portfolio
            19.1.10.3. Profitability by Market Segments
            19.1.10.4. Sales Footprint
            19.1.10.5. Strategy Overview
                19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Recommendations

Healthcare

Prosthetic Heart Valve Market

October 2023

REP-GB-666

314 pages

Healthcare

Psychotropic Drugs Market

October 2023

REP-GB-9134

306 pages

Healthcare

Prostate Health Market

January 2023

REP-GB-14282

301 pages

Healthcare

Prostate Cancer Market

December 2022

REP-GB-16210

287 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Castration-Resistant Prostate Cancer (CRPC) Treatment Market

Schedule a Call